CABG Medical faces dissolution
This article was originally published in The Gray Sheet
Executive Summary
A shareholder meeting will be held April 27 to vote to dissolve the firm, allowing for a distribution of $1.20-$1.47 per share to shareholders, equal to $22 mil.-$27 mil. in aggregate. The move comes after the company failed to engage in any discussions "that management believes could reasonably lead to an acquisition offer." The news follows the firm's failure to complete a satisfactory clinical trial for its Holly Graft paclitaxel-eluting coronary bypass system (1"The Gray Sheet" Feb. 13, 2006, p. 8). In addition, the firm has fired seven of its 11 employees as losses mounted to $9.7 mil. for 2005, compared to $3.5 mil. in 2004, primarily due to paclitaxel licensing payments to Angiotech...
You may also be interested in...
CABG Medical Winds Down Operations Following Holly Graft Disappointments
CABG Medical's board of directors has decided to dissolve the company if it cannot find a buyer in the near future
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.